Arcturus Therapeutics is trading 8.6% up at $11.94, following coverage of its regained global rights to KOSTAIVE.
- Shares rose 6.91% on August 20 and 25.21% on August 19.
- Coverage also highlighted a $12 million payment, approximately $16 million in liability relief, and progress across its rare-disease pipeline.
- No new August 21 company announcement was identified; broader indexes are modestly higher while biotech is lower, suggesting continued company-specific momentum.